uniQure NV QURE 深 沪
已收盘 08-14 16:00:00 美东时间
48.62
+1.560
+3.31%
华盛通- 最 高48.70
- 今 开47.06
- 成交量 95.77万股
- 最 低 46.31
- 昨 收 47.06
- 总市值 33.73亿
- 52周最高 71.50
- 市盈率 静 --
- 换手率 1.38%
- 52周最低 8.73
- 委 比 59.79%
- 总股本 6936.64万
- 历史最高 82.49
- 量 比 0.83
- 振 幅 5.08%
- 历史最低 3.73
- 每 手 1
- 风险率 14.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
Barclays Maintains Overweight on uniQure, Lowers Price Target to $60
Barclays analyst Eliana Merle maintains uniQure (NASDAQ:QURE) with a Overweight and lowers the price target from $65 to $60.
07-30 19:55
财报速睇 | uniQure NV 2026财年Q2营收0.06亿美元，同比增长11.0%；归母净利润亏损0.81亿美元，同比亏损扩大114.9%
华盛资讯7月29日讯，uniQure NV公布2026财年Q2业绩，公司Q2营收0.06亿美元，同比增长11.0%，归母净利润亏损0.81亿美元，同比亏损扩大114.9%。
07-29 19:35
财报速睇 | uniQure NV 2026财年Q2营收0.06亿美元，同比增长11.0%；归母净利润亏损0.81亿美元，同比亏损扩大114.9%
华盛资讯7月29日讯，uniQure NV公布2026财年Q2业绩，公司Q2营收0.06亿美元，同比增长11.0%，归母净利润亏损0.81亿美元，同比亏损扩大114.9%。
07-29 19:19
uniQure Q2 EPS $(1.22) Misses $(0.82) Estimate, Sales $5.800M Beat $5.467M Estimate
uniQure (NASDAQ:QURE) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(0.82) by 48.78 percent. This is a 76.81 percent decrease over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $5.800 million which...
07-29 19:07
uniQure to Announce Second Quarter 2026 Financial Results
uniQure N.V., a gene therapy company, will report its second quarter 2026 financial results on July 29, 2026, followed by a conference call at 8:30 a.m. ET. The event will be webcast on uniQure’s website, with a replay available for 90 days. Analysts can join the call via dial-in numbers provided. The company specializes in developing gene therapies for severe diseases, including hemophilia B, Huntington's disease, and Fabry disease.
07-22 11:05
美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for Applied Materials Inc (NASDAQ:AMAT) from $550 to $750. Keybanc analyst Ste...
06-29 21:05
What's Going On With Capricor Therapeutics Stock On Friday?
Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday, down by 13%. The Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) of the U.S. Food and Drug Administration (FDA) is planning to convene an advisory committee meeting to discuss the company’s Biologics License ...
06-27 02:06
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
